Truist Securities downgraded Alnylam Pharmaceuticals to Hold from Buy and significantly lowered its price target from $315 to $225. This analyst action signals a more cautious outlook on the company's future performance and could lead to negative short-term pressure on Alnylam's stock price.
Truist Securities downgraded Alnylam Pharmaceuticals (ALNY) from a Buy to a Hold rating on November 2, 2026, simultaneously slashing its price target by 28.6% from $315 to $225. This action reflects a more conservative view from a significant financial institution, likely due to concerns about future growth prospects, competitive landscape, or pipeline developments not detailed in the filing. For traders, this is a negative short-term catalyst for ALNY, as downgrades often lead to selling pressure. The long-term implications depend on whether other analysts follow suit or if the company can deliver positive news to counteract this sentiment, but the immediate risk is downward price movement.